Skip to content

Regulatory Considerations DMEG Update

Date: December 4, 2025

With mixed feelings, we share that Silvia Pérez Torres, current chair of the ACDM Regulatory Considerations DMEG, will step down after five years of dedicated service. As a founding member, Silvia helped launch the DMEG in February 2021.  Silvia set a clear vision, built a high‑performing, inclusive team across the world, and cultivating a culture of collaboration and excellence across the group and the wider ACDM community.

Under Silvia’s leadership, the DMEG coordinated consensus feedback to regulators on key publications from ICHEMA, and FDA, and translated evolving requirements—such as ICH E6(R3), ICH E8(R1), FDA Digital Health Technologies, Data Monitoring Committees, and the Q&A on Electronic Systems, Records, and Signatures—into practical guidance and best practices for data management. She also helped connect the community through initiatives like the Hot Topic session on ICH E6(R3) and the ACDM publication, “Getting Started with Audit Trail Review in Clinical Trial Data.”

Thank you, Silvia, for your leadership, team building, and collaborative spirit—your impact on our community is lasting.

Looking ahead, Linda Shostak, a current DMEG member, will assume the chair role in January 2026. Silvia and Linda will work closely to ensure a smooth transition and continued momentum into 2026. Please join us in thanking Silvia for her outstanding service and in welcoming Linda to her new leadership role.

If you are interested in learning more about the Regulatory considerations DMEG or are interested in joining the group you can locate us on the ACDM website here.

 


 

Explore More News

European Medicine’s Agency – Reflection paper on the use of artificial intelligence in the lifecycle of medicines

The EMA has opened a public consultation on a reflection paper presenting views . . .

Read More

Welcome Instem as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Instem as a new . . .

Read More

Regulatory Considerations Expert Group reviews draft FDA Guidance

The ACDM Regulatory Considerations Expert Group have reviewed and submitted comments on . . .

Read More

ICH GCP E6 Revision 3 is here. Regulatory Considerations Expert Group to review

The R&D industry, especially those that are working on clinical trials, have been . . .

Read More

Welcome Algorics as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Algorics as a . . .

Read More

Consultation response on legislative proposals for clinical trials

The MHRA have published the public consultation response to the proposals to reform the . . .

Read More

New MHRA Guidance

The MHRA have published new guidance on ‘Software and Artificial Intelligence (AI) as a . . .

Read More

FDA Guidance for Industry 

The FDA has issued a final guidance to provide information on risk-based approaches to . . .

Read More

Guideline on computerised systems and electronic data in clinical trials

The European Medicines Agency (EMA) have published the new guidelines on computerised . . .

Read More

Welcome IROS – Insights Research Organization & Solutions as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome IROS – Insights . . .

Read More

Recommendation paper on decentralised elements in clinical trials

Following their meeting on 4 Oct, the EMA/HTAs and EC have published a recommendation . . .

Read More

Welcome George Clinical as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome George Clinical . . .

Read More